31.01.2013 • News

Dow Chemical Q4 Profit Misses View

Dow Chemical posted lower-than-expected adjusted profit on Thursday, as demand withered for polyurethane and chlorine around the world, especially in China and Europe.

For the fourth quarter, the net loss widened to $716 million, or 61 cents per share, from $20 million, or 2 cents per share, in the year-earlier quarter.

Excluding one-time items, the company earned 33 cents during the quarter. By that measure, analysts expected 34 cents per share, according to Thomson Reuters I/B/E/S.

Sales fell 1% to $13.92 billion. Analysts looked for sales of $13.69 billion.

Repairs and shutdowns to facilities that make chlorine dented sales of the crucial chemical. Dow Chemical is the world's largest chlorine producer.

Results were especially weak for polyurethane foams, coatings and paints, and electronic materials.

The sharpest drop in volume, the physical amount of product sold, came in Europe, draining overall results.

"Weak volumes in Europe definitely held them back," Deutsche Bank analyst David Begleiter said of Dow Chemical's results.

China also proved a weak spot. "The second half of 2012 saw significant deterioration in the markets we serve, particularly in China," Dow Chemical Chief Executive Andrew Liveris said in a statement.

In an interview on the CNBC cable news channel on Thursday morning, Liveris said he expects sales in China to improve in 2013.

Last fall, the company said it was worried more about deteriorating sales in China than the U.S. fiscal crisis.

Dow Chemical took a $990 million charge in the quarter, part of a plan announced in October to lay off 5% of its workforce, close 20 plants and write down the value of its underperforming lithium ion battery business.

 

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read